M&A Deal Summary |
|
|---|---|
| Date | 2015-07-27 |
| Target | Allergan Generics |
| Sector | Life Science |
| Buyer(s) | Teva Pharmaceutical Industries |
| Sellers(s) | Allergan |
| Deal Type | Divestiture |
| Deal Value | 40.5B USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1901 |
| Sector | Life Science |
| Employees | 35,001 |
| Revenue | 15.8B USD (2023) |
Teva Pharmaceutical Industries is a provider of pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceutical Industries was founded in 1901 and is based in Tel Aviv, Israel.
| DEAL STATS | # |
|---|---|
| Overall | 19 of 23 |
| Sector (Life Science) | 18 of 20 |
| Type (Divestiture) | 3 of 4 |
| State (California) | 4 of 4 |
| Country (United States) | 12 of 15 |
| Year (2015) | 2 of 5 |
| Size (of disclosed) | 1 of 14 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-05-05 |
Auspex Pharmaceuticals
San Diego, California, United States Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. It is a developer of innovative medicines for hyperkinetic movement disorders and other rare diseases. |
Buy | $3.2B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-08-03 |
Immuneering
Cambridge, Massachusetts, United States Immuneering is a trusted advisor to pharmaceutical companies, pioneering new analyses to identify biological insights that improve patients’ lives. Immuneering’s team of experts provides advanced data analysis services using state-of-the-art technologies including proprietary algorithms. The company is a rapidly growing company with seven years of experience analyzing data sets ranging from gene expression (microarray) data, to single-nucleotide polymorphism (SNP) data, to protein concentration data, to clinical metadata, to next-generation sequencing (NGS) data including RNA seq, exome sequencing, and whole-genome sequencing. Using these data sets, Immuneering captures difficult-to-find signals, generates biological hypotheses, and designs follow-up studies, contributing to the development of medicines for patients with a wide range of serious diseases. Immuneering was formed in 2008 and is based in Cambridge, Massachusetts. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1948 |
| Sector | Life Science |
| Employees | 11,400 |
Allergan, Inc. is a pharmaceutical company. Allergan's products include ophthalmic pharmaceuticals, dermatology products, and neurological products.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 3 of 3 |
| State (California) | 2 of 2 |
| Country (United States) | 3 of 3 |
| Year (2015) | 1 of 1 |
| Size (of disclosed) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-12-02 |
Allergan - Obesity Intervention Division
Irvine, California, United States Allergan, Inc. - Obesity Intervention Division is a manufacturer and sells weight loss solutions comprised of the LAP-BAND® adjustable gastric banding system and the ORBERA™ intra-gastric balloon system. |
Sell | $110M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-08-10 |
Oculeve
South San Francisco, California, United States Oculeve, Inc. is a development-stage medical device company focused on developing novel treatments for dry eye disease. |
Buy | $125M |
